Blood Pressure Drug Linked to Active Brown Fat
Adults taking losartan showed more brown fat on scans, though the link has only been tested in mice and cells so far.
Updated on Nov. 3, 2026 in Health

Live Poll
Would you take a common medicine if it might also boost calorie burning?
Researchers reviewing medical records of 101,243 cancer patients found that people taking the blood pressure drug losartan were more likely to show active brown fat, a fat type that burns energy. The findings, drawn from patient scans and mouse and cell experiments, show an association only and need confirmation in people.
Why it matters
Brown fat burns calories to produce heat, and in this cohort its presence tracked with lower rates of type 2 diabetes and chronic ischemic heart disease. Because the link is observational, New Yorkers should read the result as a research lead on how a common medication might affect metabolism rather than a reason to change prescriptions.
This was a retrospective review of records from Memorial Sloan Kettering cancer patients, with each brown-fat patient matched to roughly two without it on age, sex, body mass index and outdoor temperature. Direct testing in mice, where losartan raised energy use and oxygen consumption, and in cells supplied the mechanistic evidence, but the human findings remain observational.
The players
Memorial Sloan Kettering Cancer Center
A New York cancer center widely known for oncology research and treatment, which supplied the PET scan records.
Rockefeller University
A New York research university known for biomedical and neuroscience research, where the study was led.
Weill Cornell Medicine
A New York medical school and hospital affiliate known for clinical research, where the first author holds a post.
The details
Losartan activated PPAR-gamma, a protein that acts as a master switch for fat cells, and a breakdown product of the drug rather than its blood pressure effect appeared to drive the brown fat response. Brown fat was identified by its uptake of the sugar tracer used in PET scans. Brown fat was more common in women, in younger patients and on colder days, which the researchers accounted for in their matching.
Timeline
Records from Memorial Sloan Kettering PET scans were pulled for the study covering 2018 to 2024.
Medications patients were taking in the month before each scan were recorded and checked.
Health Landscape
Brown fat has drawn attention as a possible target for metabolic disease because adults who carry it tend to have better metabolic profiles. This study points to losartan, a widely prescribed blood pressure drug, as a possible route to activating it, though that remains to be tested in people.
Losartan is not a weight-loss drug, and this finding does not support starting, stopping or changing any medication. If you take a blood pressure medication and have questions about metabolism, bring them to your physician rather than adjusting anything on your own.
The takeaway
Brown fat is a promising metabolic target, but this link between losartan and brown fat is observational and needs confirmation in people. Anyone with questions about how their medications affect metabolism should discuss them with a physician.
Further reading
Explore more on Weight Loss to see how researchers are studying metabolism beyond calorie counting.
Live Poll
Would you take a common medicine if it might also boost calorie burning?





